TRANSCRIPT 🔗
WEBVTT
00:00:27.000 --> 00:03:58.000
podcast, we learned together from the best scientists and thinkers alive today about how your mind body reacts to what you feed it. Before starting Mind & Matter, I spent 10 years in academia doing scientific research. I got a PhD in neuroscience from Harvard University, where I focused on neuroendocrinology and the neuroscience of behavior, and before that I specialized in molecular, developmental, and evolutionary genetics. I used my scientific background to parse and translate the information guests share on the show, and in addition to the podcast, I rate long form content and send out a free weekly newsletter at the Mind & Matter Substack at mindandmatter.substack.com. I also offer private, science-based health consulting, where we work one-on-one and apply the same rigorous evidence-first approach you hear on the podcast, the personalized. We can obtain and analyze your biomarkers, work on diet and behavior strategies, review supplements, and drugs that you might be taking, or anything else related to general metabolic health. If you'd like more tailored guidance on your personal health, head to nickjikomes.com and fill out a short form or book time with me there. A great way to support my content in all of its forms is simply to visit mindandmatter.substack.com. You'll find a link to that in the episode description, and you'll also find a link to my current affiliate partners through my support page. These are products that I use myself that relate to physical, metabolic, or mental health. For example, one product I use every day is the AquaTru water filter, which removes heavy metals, microbes, and endocrine disruptors. You name it so that you have higher quality drinking water. All of those links for health consulting, for my affiliate partners, and the substack page are all in the episode description. So thank you very much for listening, and don't forget to check out mindandmatter.substack.com for all of my content. Hey everyone, today's show is supported by Brain Bean Coffee. Brain Bean is my new go-to coffee every morning. It's clean, it's smooth, and you're going to feel good about drinking it. Brain Bean in general is one of the richest sources of polyphenols in the modern diet, especially something called chlorogenic acids. Research has linked chlorogenic acids to brain and metabolic health in different ways, but the problem is that conventional roasting burns most of them off before the beans reach your cup. Brain Bean saw this with smart roasting, which is a proprietary process they design and implement to preserve the coffee's delicate balance of polyphenols. So in Brain Bean, you get something like 447 milligrams of chlorogenic acids in every cup, which is 2 to 5 times higher than other coffees on the market. Brain Bean is USDA organic and comes from a sustainably farmed single estate. Every lot is third party tested for molds, micotoxins, heavy metals, and pesticides. They sent me a bunch
Load full transcript
of their testing literature, so I've looked at it myself, and they do a lot of testing, which I like. If you're looking for an enhanced version, they also have a Zen blend coffee, which is the same smart roasted beans infused with things like L-thienine, alpha-GPC, which has Choline and MCT, medium chain triglycerides. It helps keep you calm so you can carry on with your day. Head to brain-bean.com and use the code Mind Matter 15 for 15% off your order. They've also got other stuff too, so check that out. I like their grass-fed colostrum product. I actually put it right into my coffee. They've got collagen peptides and lots of other good stuff as well. So check out the link in the episode description or go to brain-bean.com, which you can also find on my support page at mindandmatter.substack.com and use that code Mind Matter 15 for your 15% off discount today. Robin, thanks for coming back out to the podcast. Thanks for having me back, Nick.
00:03:58.000 --> 00:04:00.000
Great to be here.
00:04:00.000 --> 00:04:08.000
For those who didn't tune in to the first conversation a couple of years ago or who don't know who you are, do you want to give people just a quick intro of what you do? Sure, yeah.
00:04:08.000 --> 00:04:48.000
So I'm Robin Carhart-Harris, I'm a professor at University of California San Francisco. I'm in the Neurology and Psychiatry Departments and I run a lab, the Carhart-Harris lab, focused on research with psychedelic drugs, looking essentially at how they work. And you could say there's two components to that. How do they work in the brain, in the mind, to generate a psychedelic experience and how do they work as psychedelic medicine to treat mental illness and potentially better mental health?
00:04:48.000 --> 00:04:59.000
And let's just mention it up top. You've got a new book that's out slash coming out. So what's the book all about? Yeah, it's about how psychedelics work.
00:04:59.000 --> 00:06:32.000
You know, I played with a few different pretentious titles before I read a book called Right Useful Books and I was like, oh, thank you. Yeah, yeah, I should just like cut to the chase. What's it about? It's about how psychedelics work. And yeah, like I said, in terms of the lab's focus, how do they work in terms of altering brain function to account for the psychedelic experience in all its wonderful depth and variety. And also how do they work therapeutically? So that's essentially what the book's about. I mean, it's somewhat personal in terms of covering my journey into psychedelic science, what turned me on to psychedelics in the first place. No spoiler there really that it was a psychedelic experience, but that's described. So a few personal experiences are peppered in. There's a lot on patient experiences in our trials. And yeah, so it's both personal. It's quite deeply psychological, I would say, quite philosophical at times, a little bit of spirituality, a good dose of neuroscience and a good dose, really, yeah, full
dose of psychiatry and mental health research. What's you actually acknowledged?
00:06:32.000 --> 00:06:54.000
I believe in the acknowledgement section, some of your early trip buddies as influences on you. Let's start with your personal experience that kind of got you down this track. It sounds like that earliest experience you had affected you and probably somehow affected the path you went on to get where you are today. Would you mind telling us that story of your first experience with psychedelics?
00:06:54.000 --> 00:14:19.000
Yeah, it's funny, you know, I used to kind of hide it, I guess the politics of psychedelics was such that people were nervous about this to be so open. There's even some research on the broader scientific communities perspective on psychedelic researchers and if they declare personal experience, it's seen as a bias and they're somehow seen as less a scientist. So I guess I was right in a sense to hold it back, but then that's really sad and it lacks transparency. And so when writing this book, I want it to be honest and upfront. And so that first experience was at the tender age of 14. It was with a couple of friends of mine in the summer holiday period back in the UK on the south coast, the town of Poul, which is close to Bournemouth. And yeah, I was with my friend Ashley Williams and I think he'd be okay with me, say. And he'd scored some LSD, a Golden Microdot each and we were to meet up with Patrick, Patrick Gough from school and to have this experience. And so I remember being sat by some beach huts down at Canford Cliffs just as it leads onto the boardwalk, what we'd call the promenade down there with a beautiful English channel in front of us. And we opened up this bit of sort of, you know, cellotape that had the microdots in and then kind of, you know, ate them tiny little things and sucked on the tape. And I remember Ashley saying it was like cold keys. It tastes like cold keys. And you know, give it, give it 45 minutes or so and things start to feel a little weird. I wasn't anticipating quite the flavor of things, you know, I didn't know really what to expect. I thought it would be, yeah, I was very naive. I mean, I was a young teenager and I thought you would see things on psychedelics. That's what I'd heard about LSD that you see things, maybe funny things like cartoonish. And so I got a real shock that it was deeper than that. It was more profound than that. It was more serious than that. And yeah, it shocked me into some kind of fear about what was going on. I was, you know, puzzled and confused by it. and the explanation I came up with for what was going on was sort of matched the dramatic of the experience itself. I thought I died. I thought oh maybe what's happened here is that I crossed the road away up and had been hit by a car and my you know my dead body is back there on the street somewhere and now I am in some kind of limbo or afterlife. It was that you know unusual that I that was the kind of you know effort and an explanation under the influence that I could come up with that my consciousness was so altered because I had effectively died. And so that gave it this flavor of you know fear what have I done guilt I've done something bad I've taken drugs and this is the universe's sort of justice dose of justice for such a sinful act as to take a a dangerous drug drugs being bad and you know my family didn't know I was doing it I was doing something that was a betrayal to them and this was my come-upence you know this this was God or whatever sort of his sort of sentence for me in a sense and so it was flavoured by all this this guilt and sort of nightmareish hellish kind of quality so it was really quite unpleasant and I wasn't sharing that with my friends I was with yeah I was so young and we weren't I wasn't particularly open I think the the nature of our relationship and our maturity which which we lacked was such that I wouldn't be open with my emotions with my thoughts there's a lot of the near of like you know performing trying to be cool that kind of thing um but uh yeah there was a lot of content I mean I can't go into it all but I would say that it left me just deeply deeply curious about what the hell was that and am I still here I seem to still be here I go back and I see you know my brother at the front door he lets me in my mind I'm like you don't know what's happened and uh will let will anything ever be the same again my parents were out and I was nervous about seeing them they were at work um and just gradually you sort of get on with with life and an ego consciousness but I'd seen this other side um and it I couldn't let it go you know it it so deeply profoundly affected me I couldn't say whether it was good or bad there was some delusional ideation during the sort of calm down period but it soon kind of um kind of went away and I just got on with things and only really in reflection can I say yes I was changed I started to become more interested in in the mind um in philosophy uh in um certain like styles of music and the culture around it John Lennon appears on my on my wall a huge poster was intrigued by him I was listening to the doors and you know I guess I went from this sort of underground dance music that was always still there that probably influenced me taking the psychedelic in the first place to be more reflective um and without question the rest of my life the course of the rest of my life was was so clearly
00:14:19.000 --> 00:14:50.000
impacted and sort of redirected by that early experience yeah yeah in the intro you write that psychological rebirth is recurring theme of the psychedelic experience you quote all this Huxley who wrote about his first trip I believe with Mescalin and he said that it was like I was seeing Adam seeing what Adam had seen on the morning of his creation the miracle moment by moment of naked existence were there echoes of something like that in your experience that you had been
reborn
00:14:50.000 --> 00:17:35.000
or that things were just different now there's more that things were different now I mean the rebirth myth story um you know we know that I mean myth as in story narrative I don't mean that it's not true uh quite to the contrary it's deeply true um but in that poetic sense um so so the the the rebirth story is the ultimate story it's the one I myth as Joseph Campbell would say it's the ultimate human story if not as the story of of existence of of maybe life um and did it it didn't obviously have a rebirth quality that was positive I'm just squaring with people here it's very easy to romanticize psychedelics I you know if anything was it was it somewhat jarring was I impacted in a negative way I'm not sure I could even say that given the way things have gone for me in life but um but I was certainly changed and I guess sort of in that alchemical sense of profound change that there was a transformation no doubt about it was it a transformation that I could color like a like a rebirth where being reborn is coming back to life with the freshness with uh like with a rejuvenation I'm not sure I could say that in relation to that first experience I had if I missed so so the experience was profound it was strong but it wasn't necessarily fun or pleasurable I'm not sure if you would say you had a bad trip but it was it was intense it wasn't uh all fun in games it was in terms some aspects of it were were bad in the sense of being unpleasant and distressing um and yeah I mean I didn't look to my friends and say I want this to stop that was still somewhat hidden and unspoken um I guess I was I was also going with the flow of it I mean we were walking around around this kind of quite pleasant seaside suburbia um but um we weren't quite reflected we didn't have our eyes closed um so it it was a yeah a lot a lot of distortion of what
00:17:35.000 --> 00:18:01.000
was around us um yeah yeah and so the first chapter is called consciousness matters so what is that chapter all about and and why did you choose to start there yeah I guess it's a fundamental with psychedelics in terms of how do they work that they work on conscious experience there's no
00:18:01.000 --> 00:23:04.000
side stepping that you know I had a bit of a healthy exchange with my editor on that who was like do you really want to go deep on the on consciousness and the philosophy of mind and I said I got I got a there's no other way here because it's it's it's kind of front and center it's it's very basic and important and I can't bypass this stuff um uh if psychedelics are interesting and maybe important uh to you know understanding examining uh anything it's because of the profundity of their action on subjective experience on the basic um essential component of consciousness and so I just knew I had to go there and break it down so in a sense that title consciousness matters was sort of like a note back to my editor like this stuff really matters like I got to do this um but also to the reader um uh more generally um and yeah okay there's a bit of a play on matter on materialism perhaps um a perspective on the mind body problem that um I don't associate myself with I think others maybe sometimes straw manning uh cognitive neuroscience or an effort to understand how brain function maps to subjective experience uh those those you know doing the act of straw manning of of making the neuroscience seem weaker than it is often go to hard materialism you know that all subjective phenomena are a mere sort of epiphenomena of material mechanistic actions, biological actions, physical actions, and nothing more than that. There's sort of secondary to the mechanics of biology and the brain, and that's hard materialism. Brain causes mind, brain causes experience. And that's part of the picture. I feel that's undeniable given what we know about brain function and how it relates to subjective experience. But it's not all that one way. It's not as linear. It's not as exclusive as brain causes mind. And so I had to lay that out and break it down. And again, square with the reader and say, hey, everyone, don't project onto me that I'm a hard materialist. There's going to write a book about how psychedelics work that says, you know, it's x, y, and z interacting that causes all the subjective experience. And you don't need to be interested or excited about the subjective experience because it's all, you know, a secondary epiphenominant of the mechanics. People could easily think, oh, Robin, he's that neuroscientist. They might think, oh, he said this stuff about the default mode network and psychedelics. And yeah, and then really miss miss the point and, you know, really misunderstand. I would say my perspective on mind and brain and the action of psychedelics. So I had to sort of lay out my philosophy and explore alternative philosophies and perhaps say why I don't align with those. You know, there are certain aspects of the philosophy like the hard problem. You know, David Sharmer's hard problem. How do you get the wine of consciousness? Is it from the water of brain function? How does that miracle, apparent miracle happen? Yeah, I had to go there. And it's really tricky, you know, it's easy to get kind of annoyed with the hard problem and almost want to just dismiss it. But I actually think, you know, it's somewhat Darwinian. You know, the hard problem stuck around. Because it's working on that, it stuck around. Because it's genuinely hard, you know, and there is something that has to be said and done to address it. And so yeah, I felt like I had an obligation. The book wouldn't have been complete had I not have covered some of the philosophy early on. Yeah, that's where that chapter is.
00:23:04.000 --> 00:23:29.000
Again, I don't think we're going to have a two hour philosophy of mind discussion here. But, yeah, but you know, today, what is your perspective today given everything you've done and thought about
on the relationship between mind and matter? Do you generally think that subjective states come from physical brain states and that consciousness is strictly in the brain or do you have a different perspective? Yeah, I have a different perspective.
00:23:29.000 --> 00:30:03.000
But I don't think that all subjective experience comes from in a linear causal way. I think there are the causation is circular. There are processes that run in parallel and the causation can also come from a higher level in terms of the psychological phenomena leading the biology. And I'm quite sure of that now, the mental phenomena that aren't divorced from biological phenomena, they still run parallel with. But in terms of the weight of influence and causation, it can come from mind. And that is legitimate to say. And it's not some kind of wishful thinking, it's not some kind of mysteriousism, it's not some kind of hard dualism, it's certainly not some idealism that mind is fundamental when everything else is epiphenomenal. It's not as hard and absolute as that. And if you give it a formal name, I would align with dual aspect monism, that there are two ways of looking at this thing. One is to look at the subject of experience, the psychology and to experience it first hand. And then the other is to look at the biology that maps to it. You might say the encodes for it, yeah, I'm runs parallel. So the way that we write our papers often in cognitive neuroiscientive, it's like looking at the psychedelic experience is to talk about neuro correlates. To talk about correlates. And I think what's happened is that people have thought, oh but correlation isn't causation, correlation is just the easy problem. Charmers would say that, you know, what goes alongside and then they demand or charmers might demand whether he's aware of it or not, that we be more concrete in our allegiance to the causal question, what causes what? And how do you get the wine of consciousness from the water of brain? And I'd say but it's not a matter of one thing causing the other. You're asking me to commit to hard materialism. And I don't see it that way. I see the causation as circular, as complex. I see mental phenomena, experiential phenomena as being legitimately emergent without any magic there. There'll be a mathematics to it, no doubt, there'll be a physics to it where things can emerge from the parts contributing. So the whole is somewhat say greater than the sum of the parts. And I think we share a mutual appreciation of Deacon, his work on this and blanking on his first name, but Terence Deacon. Terence Deacon, a Berkeley. And he's a fantastic writer and thinker and I love his twist on this. That gestalt principle of the whole is greater than the sum of the parts. He says, no, it's more that the whole is less than the sum of the parts, that there's a collapse, that there's a data compression when you catch the gest. And that's emergence. That's an emergent singular thing, maybe from a number of components contributing to that emergent singular thing, let's say. In my mind's eye, I see the kinesa triangle, where you see a white triangle that isn't there, but you're seeing it because you have these black shapes, three of them, contributing to tease the inference that there's a white triangle there that's not there. That's an emergent perceptual phenomenon. But it's a very nice illustration of emergence. And Terence Deacon's point, the whole is less than the sum of the parts. It's one and not three. So yeah, this is my perspective and it's why I like to give as much attention and careful thought to the psychology that I'll give to the biology, to the neuroscience, the matches. And you know, it's a way that we do our work that we often side with the camp. Are we a psychologist? Are we a neuroscientist? And neuroscientists often might think like a hard materialist that it can all be collapsed down to brain. The psychologist might be so immersed in the psychology, the phenomenology that they almost dismiss brain and think, oh, that's the other thing, it's not important. Yeah, I like to try and hold each side with and give it equal attention, equal weight. I sort of feel if you don't do that, you run the risk of neglect either way. So yeah, it's a big part of my philosophy and approach. And it very much, you know, leads into, yeah, very much how I do my work. I probably read as much neuroscience as I do psychology. And if I feel like I'm giving either side too much attention. and I try and rebalance it. Yeah.
00:30:03.000 --> 00:30:34.000
So if hard materialism is just the idea that the biology leads the psychology, that, you know, mind or subjectivity, it's just the exhaust fumes, epiphenomenal exhaust fumes of whatever's happening in the brain. If your view is more like, well, the brain stuff can drive psychology stuff, but also psychological stuff or subjectivity can drive biological stuff. What might be an example of, as you might say, the psychology leading the biology?
00:30:34.000 --> 00:33:17.000
Yeah, well, a great one is a placebo phenomenon. You know, and it's funny that that is so influential in medical research, yet it's a psychological phenomenon, you know? Medical research prides itself on a close alliance with hard science and biology is always looking for where are the biological targets where can we reduce it down to? You hit this particular protein, for example, and you'll get the medical solution. But the reality is more complex and one reflection of that is that, you know, the gold standard way to assess it, new treatment, certainly drug treatment is to run a placebo controlled trial. And so there is a recognition of that psychological phenomenon that no one's saying it doesn't have a biological counterpart. I mean, there's great science on that that you can give a placebo and tell people it's a painkiller and then see the release of naturally occurring painkillers in dolphins, you know, naturally occurring opiates or
opioids in the brain. And so we have very compelling evidence that mind can lead the biology, you know? And yet people make these claims around determinism that it's all billiard balls, you know, bashing into each other, causing the epiphenomenon of subjective experience. And it's doing such a disservice to subjective experience and phenomenology and the importance of that space. Everything that all of us have ever cared about has occurred in the domain of subjective experience. It's really so fundamental to who we are and what we are. And so to try and write it out of science, of studying stuff, it's kind of offensive, it's absurd. And yet it's part of the scientific culture or has been for a long time. I do wonder whether that might change and we're seeing a bit of a cultural shift on that front, a hope so, because it's really an error to see things that way.
00:33:17.000 --> 00:33:47.000
Yeah, I mean, the placebo effects are a great example. Like someone's expectations, their beliefs about what's happening about the pill they're swallowing or whatever, it's literally changing something inside of them and it's having real effects. You gave the example from the pain literature, you can have actual release of endogenous endorphins simply by believing that you're taking something and unbeknownst to you, it's a sugar pill. And of course, expect patients are really important in terms of sculpting the psychedelic experiences,
00:33:47.000 --> 00:36:14.000
almost anyone who's had more than one can tell you. You can take the same dose of the same substance and your expectations the second time or being in a different environment can profoundly change the biological effects that are actually being instigated by the drug. Yeah, I'd like to say something about that though, because there's some initially surprising evidence on the role of expectation in relation to response to psychedelics. It's well established with the placebo phenomenon and it's really quite impressive efficacy, let's say in treating pain or treating depression that something entirely inert can be pretty effective in dropping the pain, dropping the depressive symptoms, symptom severity. And yet that rule that is very, very powerful and sort of underrides or justifies or motivates the use of placebo in controlled trials, that rule quite surprisingly, at least initially, does not seem to apply so strongly to psychedelic medicine and response to it. So there've been a number of studies now. We've run a few of these, we've seen it in depression, we've seen it in anorexia, we've seen it in fibromyalgia syndrome, chronic pain, that when you measure people's expectations for response to the psychedelic ahead of giving the treatment, the variance in people's expectations, so some might think, oh, this is a dead sir, it's gonna cure me entirely to this ain't gonna work, nothing works for me, so that's your variance, you'll have a spread there in your expectations, and then of course you'll have
a spread in response, some will do really well, some won't do very well at all, they won't respond. Is there a relationship between the two and we found in psychedelic medicine in testing this that there isn't? So pre-treatment expectations for response are failing to predict actual response, and this is replicated. Yeah, so based on what we know about the placebo effect, based on what you might guess from just common sense,
00:36:14.000 --> 00:36:40.000
you might expect that someone who believes the psychedelics are gonna really help them a lot compared to people who don't believe it's gonna help very much at all, you might expect the former group is gonna have bigger effects when it comes to depression or whatever you're measuring, you're saying you've measured that, you measure people's expectations ahead of time, you give them a dose of whatever, and in the case of the psychedelics, there's not a correlation between their expectations and the outcome you measure clinically.
00:36:40.000 --> 00:38:36.000
That's right, and it's kind of curious. You would have thought, you know, people have rightly, I think, put this challenge to psychedelic medicine, some of them are skeptics and just doubt that it is what, you know, maybe some of the hypers have been saying, and they'll say, oh, it's like a super placebo, it's probably all driven by pre-treatment expectancy, or you've heard, you know, Michael Pollan on Oprah, or you've read his book, and it sounds amazing. Everyone's saying it's amazing, and then that drives, oh, low and behold, it's worked really well. That's been the challenge and the assumption, and I'm saying the evidence doesn't support it. In fact, yeah, there's a remarkable lack of a relationship there that's usually there. And what does it mean? You know, it doesn't mean that there is no, what I would call and the field would call, non-specific causation to the action of psychedelic therapy. What does non-specific mean? It means things like generic care, a care effect, therapeutic alliance, therapeutic rapport, you like the people who are caring for you. You trust them. There's a few of these non-specific causal factors that are often quite psychological in nature, like the surrounding context being therapeutic that seems to really matter in driving, in predicting response, and we call those non-specific causal factors. In contrast, a specific causal factor might be,
00:38:36.000 --> 00:38:39.000
you've got to hit the serotonin to A receptor,
00:38:39.000 --> 00:38:52.000
which would cause x, y, and z, which causes, response to the treatment. That would pin it all on this very low level thing,
00:38:52.000 --> 00:38:57.000
stimulating a serotonin to A receptor, let's say.
00:38:57.000 --> 00:39:34.000
That would be a specific causation. But it seems that there is a large part of a non-specific causation with psychedelic therapy, but it's not driven by what I would call, how I would break down the expectancy phenomenon, and say it is synonymous with a self-fulfilling prophecy because I believe this will work, low and behold, it works, therefore it works. Psychedelic medicine, psychedelic therapy does not seem to work via a self-fulfilling prophecy.
00:39:34.000 --> 00:39:39.000
Because you observe people who believe it will work for whom it doesn't or vice versa.
00:39:39.000 --> 00:42:22.000
Yes, yes, and often it is vice versa, actually, and depression, say, because people come in with this negative cognitive bias. Despite the hypers, nothing works for me, this ain't gonna work for me. I'll give it a shot, but it's probably not gonna work. We're definitely not gonna work. And then they have the most profound experience of their lives. They have this encounter with a dumping of kin to a guardian angel that is talking to them in loving, healing words. And this being, this spirit is encouraging a transformation telling them it's going to be okay that they're cared for, that they're loved, that they could do X, Y and Z to change their perspective and outlook and low and behold that they've changed. They have it just responded, they're in remission. And in the best of cases they stay well for many years if not the change is permanent. And I describe a case like that in my book. I think it's chapter seven, the first, it might be chapter six. But it's part two of the book and it's the focus on mental health and it was the very first patient in the very first depression trial of this modern era with psychedelics, the so called Renaissance. And it was a trial of psilocybin therapy for treatment, resistant depression. And this individual had that experience of being visited by, being in the presence of kind of, you know, divine being spirit angel that was healing them. And they responded very, very well. And I checked in with them a few months ago now when writing the book and they're still well and they haven't had another depressive episode since that treatment which is over 10 years ago now, remarkable. And that was the very first patient doesn't always go that way. Has to be said that was a particularly good case example. But it did go that way in that case. And there were rebels too.
00:42:22.000 --> 00:42:56.000
So it goes that way sometimes. And sometimes you have these, they have these profound experiences such as the one that you just described. But there's no correlation between expectations and outcome. So people's expectations don't correlate with outcome. So we can rule out expectancy effects or that psychedelics are super placebo as some people say. Is there a correlation between the intensity or content of the subjective effects and can we even really measure that? How do you even measure that?
00:42:56.000 --> 00:47:13.000
Yes, there is. And there is a relationship between the intensity and it's better said as the quality of the experience and the therapeutic outcomes. And there are a couple of constructs or phenomena that I would highlight here. And they're closely
related actually. One would be emotional breakthrough. Also known as emotional release. Also known as emotional catharsis. Well, what is that? What does that look like? It often looks like someone crying. A strong release of emotion and unburdening, turning on the taps. And all this pent up feeling that hasn't been expressed, that hasn't been released, is now being released. So when that happens, and if it happens strongly, then that's a strong positive predictor of therapeutic response. So having a fresh perspective on your life, your relationships, the world more generally, existence. Yeah, when there's insight, felt insight of that nature, then that's a strong predictor of therapeutic outcomes. So these are two closely related constructs. Sometimes there's a temporal order to things. I would say more often than not, the emotional release goes before the psychological insight. But they are closely related. And the two in combination are very strong predictors of therapeutic outcome. It's not all of it. You can't have such a simple formula, then that's it and done. But it's never that way in science. Or models are wrong, some are useful. This is a really useful model, it seems. Another component that goes, again, quite closely at covariates where it relates to these experiences is what has been referred to as the mystical type experience. The spiritual experience might be another way of saying it. The unitive experience, I think, is another good way of saying it that hints more at the mechanisms as opposed to maybe the mysteriousism that this is odd and hard to put into words, odd but profound and transformative, but really hard to put into words. I think we start to commit a bit more to the matching mechanisms. If we're willing to call it a unitive experience, a sense of oneness, a sense of interconnectedness, a sense of both a breakdown of things. So there, a term like ego dissolution would be relevant. But not just the loss of function or a loss of something, a loss of ego consciousness, but also a gain. So what's the gain? Well, the gain is the unitive experience, the non-dual awareness that I see things now as essentially and fundamentally interrelated, everything depending on everything else in relation. And that being felt as a revelation, so you could see how that would relate to psychological insight. You might also ensure how that could relate to emotional breakthrough that when you realize something like that, something so profound as that, it's very deeply moving. And you've shattered your ego tunnel through which you typically see the world. And now you're seeing it in a fundamentally different way that feels beautiful and profound. So there's a close relationship between these phenomena, but this is just getting to the core of what psychedelic therapy is and how it can be beneficial.
00:47:13.000 --> 00:47:54.000
I want to spend some time talking about psychedelic therapy in comparison to more traditional therapy. So comparing things like psilocybin for depression to things like SSRIs for depression and other things. You've done work on this, you've compared these things directly. Let's talk a little bit about depression and where it comes from and what it is to set that up. What's the clinical definition of depression and what are the criteria for diagnosing someone with depression? And how does that start to relate to how much we actually have to rely on psychiatry on what people say and the subjective aspects of their experience? Well, we do have to rely on that because that's how diagnoses are done.
00:47:54.000 --> 00:50:04.000
Typically a doctor is with a patient and patients describing their symptoms. And a doctor says, okay, it's ticking the boxes that are required for a formal diagnosis here. I'm hearing about low mood. That's one of the core factors. I'm hearing about anodonia and inability to feel any pleasure in anything. And then I'm hearing about some other domains that contribute as well to a diagnosis such as cognitive impairment and inability to think clearly, sleep problems. Yeah, a general sort of slowing cognitively and motor, so movement. And often suicidal ideation as well, being in other sort of sub-factor. But the core would be the low mood and the anodonia. Anodonia is the inability to feel pleasure. And then one from a cluster of other potential symptoms. Yeah, and so if doctor is hearing this, then they write out that prescription. It might be major depressive disorder. And then typically, patient would know that they have a couple of options for treatment. But the typical one would be that they could go and get a prescription. They could go and get a course of an antidepressant drug. And typically these days, that would be a selective serotonin reuptake inhibitor of some variety. Or something that might boost dopamine a bit and give them a bit of energy, like be appropriate on. So yeah, that's gym. the way it would gos go.
00:50:04.000 --> 00:50:17.000
Do you how do we measure the improvement in depression when you guys are doing clinical trials, whether it's with psilocybin and SSRI or anything else, what are these scales that are used and how do those actually work in practice?
00:50:17.000 --> 00:52:42.000
Yeah, so there's two different essential varieties. One would be clinician administered rating scales where doctor or some clinician typically could be a research, but better if it's a clinician is essentially doing an interview with the patient and running through some set domains. So it's like a structured interview and then rating things like the severity of the sleep disturbance that I'm hearing about, the severity of the low mood that I'm hearing about, the severity of the psilocyde-weight ideation that I'm hearing about and they give a score and then the total dark and it will give you an overall symptom severity score. Examples of that would be the like the Hamilton depression scale, we call it the HamDee, another would be the
Madras, which is a Montgomery, a depressive symptom severity scale. Those are two classic clinician administered scales. You know, where we are, with psychedelic medicines and it would be the case with other treatments that are close to getting FDA approval, very close, if not really on the cusp of it. Those studies are often resting on something like a Madras score change from baseline to post treatment at some specific time point. The other type of depressive symptoms severity scale will be patient rated so that cuts out the middle man so to speak and goes straight to the patient and asks them to read some items describing symptoms and then to rate the severity. I like those scales. I think there's special value in cutting out the middle man. You know, some call the clinician administered scales is more objective, but I'm not convinced because there's one person subjectivity on top of another's. You know, it's the clinician subjectivity on top of the patient subjectivity. So it does that equal objectivity now. Yeah, I'm not so sure.
00:52:42.000 --> 00:52:46.000
Do people ever do both and do they go on like closely with each other?
00:52:46.000 --> 00:54:10.000
Yeah, and that's what we do. I like to see that in trials. It can give you convergent validity where if both scores are both types of measure of pointing in the same direction, then you can feel pretty confident that you have a true result there. Yeah, so that's what we've done in past trials. Yeah, people wrongly think that it's some kind of fishing expedition that you're going to find the most sensitive scales and you're going to report on those and sort of cherry pick after the fact. But the reality is you don't necessarily know what the most sensitive scale is and if you use scales of a different type and they converge on the same result, then you can feel more confident in that result. And also by using more than one scale, you might see which have performed best and that can help inform whether you'll use that scale again in the future. And so it's been very, very useful to use more than one scale I found in a couple of our studies we've used four, two patient rated, two clinician rated. And it's been very helpful to have done that. Like now I feel much more confident about which scales I'd use going forward.
00:54:10.000 --> 00:54:20.000
One of the big criticisms that I've heard on psychedelic psychiatry is, well, you can't do a proper placebo control group because if you're giving someone
00:54:20.000 --> 00:54:28.000
a full dose of psilocybin or LSD or whatever, they're going to know if they got that versus the placebo. So there's this question of like,
00:54:28.000 --> 00:54:59.000
can you really do a placebo control? My question for you, Robin, is in the literature on the historical literature on SSRIs, where you're just comparing an SSRI to a placebo. SSRIs aren't going to give you an eight hour LSD trip, of course. But people can often tell if they're on an SSRI, does the same kind of trickiness come into play if even if we're just looking at all of the studies that are out there on SSRIs? And these placebo controlled trials? Is there something to be said there? There is something to be said.
00:54:59.000 --> 00:59:20.000
Yeah, so the problem is there, the problem of what's called functional blinding, like working out what you're on is also there in SSRI trials and other trials with drugs or interventions that have conspicuous effects, where the effects give the game away. Yeah, no. And yeah, it's less stark with SSRIs than it is with psychedelics. It's fair to say. If you look at functional blinding rates, which is correctly working out what you're on, those correct guesses are like 90, 95% in psychedelic medicine trials. You typically work it out, but she all the time, especially when you get the active, when you get the psychedelic. Sometimes you're not sure if you get the placebo and if you're naive to psychedelics, you can imagine, or maybe I've got the psychedelic. That can happen. But if you get the real thing, you know about it, you know? So it's a problem. It's a very legitimate problem. Is it a psychedelic medicine? Or is it a problem that exposes the fallibility of the double blind randomized control trial and the whole placebo game? Sharad, if you want. I think the latter. I think it's another case in which psychedelics, psychedelic medicine, is shining a very bright and hot spotlight on current paradigms and finding the wanting. That they have flaws, important flaws. Like, function on blinding is there and it's a problem. Why should we have to play this game? This, this, this, Sharad. If it doesn't work. If our assumptions about blinding are flawed, that people work out what they're on. You know, the placebo controlled design with blinding, hiding what patients are getting was invented for peripherally acting drugs for, you know, other domains of health, not mental health. And then they got sort of repurposed and retrofitted in a sense to psychiatry and where we find ourselves today that model is being applied to psychedelic medicine in psychiatry. And it's just the wrong paradigm given this context. So we need a different, we need a different paradigm in approach to testing the causal action of psychedelic medicine. Because that's why you have the double blind RCT. That's why you have any kind of experimental control at all is that you're trying to work out what did it. And people don't always understand that. But it is a matter of what you call causal identification. What did this? You know, imagine a charlatan on their soapbox saying, I've got this snake oil and it'll cure you of everything. And come and buy the snake oil, roll up, roll up. You know, you buy the snake oil and whatever, you're, you know, the pain in your leg. Oh, it goes away. Oh, you know, okay. So that snake oil is an effective medicine after all. Or it was some other kind of causation. So this is why we do this work is to try and
determine what the causal action is so that we can know whether the treatment is substantive or rests on some kind of snake oil charlatanism. It's empty of any real action. Even if that action is non-specific causation.
00:59:20.000 --> 00:59:24.000
I don't think there is a case for
00:59:24.000 --> 01:01:32.000
mass snake oil prescriptions placebo prescriptions in medicine. It's part of the picture, but we do want something more than that. And I very much believe that psychedelic therapy is a lot more than some kind of just snake oil empty action as I was alluding to earlier in relation to expectancy. But that's why we do the trial. So, you know, what would be other ways to cause a identification. And that's where things like mechanistic questions are really important. And so things like prediction of response modeling, looking at psychological predictors of response and also matching biological predictors. So we can look under the hood, say with functional brain imaging, at certain things that occur in the brain, changes in brain, function, brain activity, that are part of the substantive action of psychedelic therapy. There are a few candidates there, certain signatures of the action of, say, classic psychedelics that I've found in my work and I believe are really important that when you get this effect and if you get it in a big way, you've got the opportunity you need for a healthy change. Yeah. And it's not the be all an end all, it's not that you hit that target and you just know you're going to get a response, it's not that simple, but it might be that you hit that target, you have that brain action. And if you twin it with really good supportive conditions, really good supportive therapeutic care, then you've got the secret source and then you get good outcomes pretty reliably.
01:01:32.000 --> 01:01:42.000
When you compare things like psilocybin to SSRI's head to head for depression, say, how do they compare it? Yeah.
01:01:42.000 --> 01:02:36.000
A few different ways to cut this out where we've done it before in a head to head trial, I could go to the sort of publicly available result, publishing New England Journal of Medicine where the editors tied us to the pre-registered primary outcome measure where there was a lack of a significant difference between the two treatments. I mean, psilocybin therapy was numerically better than the SSRI at the specific endpoint or specific time point post treatment. And what was that endpoint? That was the quick and ventricular depressive symptoms, patient rated, the quid's SR-16, I think it is 16 items. And it was the mean score from baseline to the six-week endpoint. So it's very, very specific.
01:02:36.000 --> 01:02:47.000
So basically you ask patients how to press, are you? Then you ask them again six weeks later, half of them got psilocybin, half of them got an SSRI, and they were not significantly different by that patient measure.
01:02:47.000 --> 01:03:21.000
Yeah, by that single one. And what the public don't know is that virtually every other outcome, if not every other outcome, every other depression, symptoms of heritiscal, other symptom domain measures like well-being and adonia, suicidality, really the list goes on, would have significantly favored the psilocybin condition, actually including the quids on certain domains like response rates. I see.
01:03:21.000 --> 01:03:35.000
So you measured all of these different things. And psilocybin did better on many of them, but it did not do better on the patient asking the patient how to press their measure. But that was the major measure that the editors said had to be the primary endpoint.
01:03:35.000 --> 01:06:23.000
Yeah, because we said, it's good practice to name one test ahead of running your experiment that you will be held to. And there's a honesty, there's a transparency to it. And it's right, it's good practice. We shouldn't change that. But you might call it kind of Murphy's Law that it was one measure in several that was the only one that I missed. So sort of like the headline measure, it's not necessarily the best measure. It's certainly not the only measure, but because it was designated, predesignated as the primary endpoint, that one perhaps got the most attention. Yeah, and rightly, it got the most attention because that's playing, you know, doing the process very thoroughly and properly. I would just say we should have been allowed to also describe the secondary outcomes. And a lot of those, it was forced on us that we had to hide them in what's called a supplementary information to the main paper. And I was uneasy with that and I felt kind of pressured into that. And so it was only in time that we started to reveal more of those. And I still say to people, please read the supplementary information for that paper because you'll get a fairer, fuller picture of what really happened. So yeah, there was some frustrations in the process. I think we played it very straight with that first report. And so I don't have any regrets in that sense. It's just, I do regret a bit that the public don't know the fuller picture of what happened in that trial. But you know, you learn a lot from running any trial. You always learn what you could have done better, that measure that missed, that was an outlier in a sense. It was a normally. I don't think it's a very good measure. And I think it's insensitive. I think it tries to cover too many ancillary domains that aren't kind of core business to depression. Some of the way it's rated and scored is unusual. And so I think there are problems with the measure and I think that's reflected in the fact that it behaved differently to virtually everything else. And I think the public should reflect on the fact that had we have chosen, you know, one of the other, let's say dozen, it's more than that measures, the whole narrative and story would have been flipped on its head. You know, New York Times headlines would have been magic mushrooms
and more effective than SSRI, I think. So you can take, in other words, you could look at, if you look at the study holistically,
01:06:23.000 --> 01:06:43.000
you look at everything, you know, depending on what you choose as your primary headline endpoint, that's right in the abstract or whatever, the journalist might write the article, psilocybin no better than SSRI's at depression because they're looking at that primary endpoint. But if you were to look at everything, you might say psilocybin better on almost every measure of depression, except for one.
01:06:43.000 --> 01:08:35.000
Yeah, yeah, yeah. So, and you don't say that because that's more details than the journalist want. You know, they always want a simple story and they also want to be faithful to what's been published and what the abstract says in the main paper. So the journal editor had a lot of power and control in that sense. You know, one of the impacts of that trial on me has been to motivate and it was published in 2021. So as five years ago now, it has motivated a lot of reflection on how we would do things better next time. And it's true that science is slow and it sort of needs to be, it's slow. But if a trial is good, the findings that it will yield will stand the test of time. And they are like farm solid foundations deeply rooted. It's not some whim. It's not someone writing their opinion in a journalistic, I don't know, blog or something. This is evidence that should really stand the test of time. So it might be slow, but it's really the strong and deep foundations of all of this, like where is this psychedelic Renaissance going, even though it exists at all. The very foundations of it is the science. And Michael Papolin wouldn't have had his book or anything really to write about had there not have been some solid science with interesting evidence coming through. So sure the process is slow, but it gives you the really kind of quality, strong, resilient information that you need.
01:08:35.000 --> 01:08:41.000
Have any other head to head trials been done between psychedelics like psilocybin and
01:08:41.000 --> 01:10:46.000
SSRI since then? No, not to my knowledge. And I would know, let's see, I know that there are some attempts to do that. There was going to be a psilocybin, I think, versus an SSRI for general anxiety disorder trial out of Australia. I'm not sure how far along that is. There are others who wanted to compare psychedelics with ketamine. I'm not sure where those are. I'm planning another heads the head. It's going to be a psychedelic therapy versus esitalopram again. This time eight weeks instead of six weeks of esitalopram eight weeks is more the gold standard sort of treatment duration. You've got to give it two months to get a good response, good enough response, but I would say that's a long time to wait. But whatever, you know, that's how long you should have a course of the SSRI to give it a fair crack of the whip, they say, versus it will be two treatment sessions with the psychedelic therapy, two dosing sessions. And this will be in young people with depression, 18 to 25-year-olds. It's a really exciting trial that we're developing at the moment. We might be six months away from first patient, first visit, maybe a little longer than that, but it's close. It's going to be a really neat trial. It's not going to be a double-blind RCT. We'll blind the clinician rated assessments rightly. We'll have randomisation, which is a staple of good clinical trial design, but we won't try and blind patients. Why, because it's silly in this context, when do you do that in actual clinical care? You come to a doctor, I'm depressed, I'm thinking about killing myself. Oh, well, I'll give you something. I won't tell you what it is.
01:10:46.000 --> 01:11:10.000
I mean, really, it's a dirt, it's silly, it's ethically questionable. And when you look at it that way, you could argue certainly that doing it the way you're suggesting, or you just tell people what they're getting, that more accurately models what actual care would look like. The doctor is going to tell you you should take this because you have this. Yeah. So the real world validity,
01:11:10.000 --> 01:12:47.000
translational validity, ecological validity is really strong if you run it in that open label way. You still have randomisation for rigor. You still have blinded assessment for rigor. You have mechanistic outcomes like brain imaging for rigor to try and achieve the causal identification. You do careful modelling, including variables like pretrial expectancy for rigor. You model it all, you measure it all, and then you have your strong inferences about what caused the outcome. And that's the trial that will be running. And so I feel really good about it. Again, it's learning from experience, running double blind RCTs and realising in the process kind of how silly it is in this context. And yet people are so influenced by things like reputation and sort of a self-consciousness about wanting to be a good scientist. They think things like the double blind RCT are just unnegotiable. We've got to do this way, it this way because NIA will expect it, FDA expect it, big works here and there will expect it. Well, they might expect it, but are they right to? Actually, I'm not sure they are. In fact, I really don't think they are. I think we need a different testing paradigm for this particular treatment and modality.
01:12:47.000 --> 01:13:37.000
So traditional antidepressants like SSRIs are serotonin reuptake inhibitors. There's differences between them in the details, but that's a core feature of them. The serotonin-based psychedelics, what are often called the classic psychedelics, psilocybin, honesty and so forth, they activate the serotonin to a receptor and then there's differences between all of them in terms of all of the other things they're touching. You've done a lot of work mapping out the whole brain dynamics of how psychedelics affect
brain activity writ large. Has that been done for SSRIs? And if so, how do general global brain dynamics and brain activity patterns compare between psychedelics, like psilocybin and SSRIs? Yeah, it's a great question. There are some similarities and
01:13:37.000 --> 01:18:15.000
differences. If I start with the differences, we've run, for example, FMRI research, looking at how people and their brains respond to emotional stimuli, social and emotional stimuli, what's that? It's typically faces showing different emotional expressions. So very simple, very basic, kind of clunky and it's simplicity, I guess. But the brain has pretty well characterized response to faces and faces showing different emotions. Certain emotions centers are quite sensitive to that stimuli type. And what you find with SSRIs, what we found with SSRIs is that the brain is less responsive, post-treatment versus pre-treatment to these faces. Quite generally, it was an attenuation of brain responsivity that generalized across neutral facial expressions, happy, smiling facial expressions and I think it was fearful, I think it was fearful emotional faces. And so it was a kind of blunting, it was an attenuation of the brain's responsivity and that's what we found with the SSRI. With the psilocybin therapy, there was less of a reliable change actually in brain responsivity, it was responsive, pre-treatment, it was responsive post-treatment. There certainly wasn't an attenuation. There was one domain of emotional expression, one of the three that was actually augmented, the brain was more responsive post-treatment and it was actually in the neutral facial expression domain. So it was kind of curious there, I mean, do we extrapolate and think that maybe post-treatment with psilocybin therapy for depression, people become more interested in what is it? Equivical emotional expressions, is this person happy or sad or what? It's a neutral facial expression, I'm interested, I want to know, was there something like that? I'm extrapolating here. We do know from the phenomenology, I mean, this is nicely characterized, both qualitatively and quantitatively, the people are more emotionally, they report feeling more emotionally connected and sensitive post-treatment with psychedelic therapy. They're more somehow attuned to the world generally but also to their feelings, to other people and what they might be feeling, it's almost as if there's a sort of theory of mind boost, incuriosity and interest in other people which is very beautiful, I think, and human. I think that's when the treatment works really well, is that you start to become more interested, more empathetic in others. I am extrapolating here but this is resonant with the more qualitative phenomenology. A colleague of mine wrote a beautiful paper on how people's psychology changes post-treatment with psychedelic therapy, with psilocybin therapy for depression, where she described two main effects. One was in the domain of emotional
acceptance, more accepting of one's own feelings whether good or bad, whether pleasant or unpleasant, more of an acceptance generally and also in connectedness and that's what I was alluding to. Feeling more connected to one's feelings, one's emotions, one's body, feeling more embodied, feeling more connected and interested in other people, so a connection to others, social connectedness, and also a sense of connection, reconnection to meaning, so an existential effect, feeling like life is worth living, that there is a purpose to this, and so that kind of multi-domain connectedness is something that we've seen run throughout our trials with psychedelic therapy for depression and a rexia chronic pain and also in
01:18:15.000 --> 01:18:52.000
healthy people too. So you mentioned, so you did the experiment where you're imaging people's brains, you're showing them visual stimuli like faces, maybe a happy face, maybe a fear-inducing face, a neutral face, people do this type of experiment quite often, and so obviously certain parts of the brain light up more than others when you see a face as compared to something else, but also if you see a fearful looking or mean face, it's gonna light up with a different flavor than a happy face or something that's neutral. So you're saying that when you show these different faces to people who received SSRIs, there is a general blunting of the response, so the responses were just sort of
01:18:52.000 --> 01:18:58.000
lessened across the board. That's right. I've had other people on the podcasts, psychiatrists,
01:18:58.000 --> 01:19:32.000
talking about SSRIs of depression, and one of the things that's come up in the past is that SSRIs, even when they're effective, someone gets a lower depression score, they're feeling less depressed. That same patient will often report that their depression is lower, but they're also just sort of emotionally flatter across the board. They're not as happy as they remember once being, even though they're not as sad at the same time, this kind of blunting of emotion in general. Do you think that you were seeing an echo of that in the FMRI experiment or not?
01:19:32.000 --> 01:21:17.000
Yeah, I think so. That was one of the inferences that we made that maybe this relates to other findings, that while you can improve symptom severity with SSRIs, drop people's depression scores, it's harder to treat the anodonia, to make people, or to help people feel more engaged with life and return that sense of yeah, interesting things and eagerness to feel pleasure in things. I guess one domain of that is the sexual dysfunction that you get with SS rise as well. And that's something that we saw in the head-to-head, the SS Rhyverse is the Salicybony therapy for depression. The Salicybony therapy if anything returns sexual functioning and correct, corrects a sort of loss of interest in sex that might be there in the depression. And there's an improvement in sexual functioning and interest and so on. Post-treatment, we've also seen that more generally in relation to psychedelic use, an improvement in sexual functioning. But with the SS Rhyse there was a very clear increase in sexual dysfunction as one of the side-effect domains. So I think that's a kind of domain-specific phenomenon that also reflects more general phenomenon with psychedelics around blunting. With SS Rhyse around blunting.
01:21:17.000 --> 01:23:10.000
Yeah, I had David Healy on a year or two ago and he talked about this sexual dysfunction that can be induced by SS Rhyse. And it's apparently more common than most people have appreciated. And sometimes it's quite traumatic. I mean, he gave examples of patients who, from the first dose, had very, very strong effects. So they have this kind of sexual dysfunction in the worst cases. It persists for a very long time even after they stop the SS Rhyse. So it's interesting that you saw a completely distinct effect with psilocybin. I wasn't actually aware of that effect. But related to the story of SS Rhyse and use sexual dysfunction, if you just sort of step back and look at sort of the general arc of history in psychiatry, of using things like SS Rhyse, in general, I'm compressing things here. Lots and lots of excitement very early on. I still remember being a small child back in the era of Zoloft commercials and everything was pretty new. And I remember magazines, talk shows, people, there was a lot of excitement. We've kind of figured out, psychiatry's really coming into its own. We've got these pills now. We're starting to get these things figured out. Fast forward to today. And one of the things that took a lot of time to realize is that perhaps there are chronic side effects that we were unaware of earlier in history because we just hadn't had enough people taking these things for long enough. If in when psychedelic therapies become more and more common, they come out in different varieties. We make novel psychedelics and so forth. Is there any worrier risk that over time we might discover that there are side effects we didn't know about earlier on or possible chronic effects that come from long-term exposure? Yes, I think so. One of the qualifiers there in favour of
01:23:10.000 --> 01:31:22.000
psychedelic medicine would be to say that it has a much longer history than SSRIs. SSRIs we've had a few decades, I guess the 80s, they were invented and then really start to be popularized from the 90s onwards. So just a few solid decades of SSRIs. And so maybe some of the side effects are starting to come through now. There's a kind of reckoning with psychedelics mixing them up with SSRIs rather. Yeah, there are some insidious side effects that might be quite hard to detect but nevertheless are important and seriously problematic. I think for some people this blunt can manifest almost as a sort of callousness like caring less. Maybe even caring less about consequences. I guess you have sexual dysfunction. So couples that say in a
marriage aren't having sex and the SSRIs being taken chronically for many years that there's no sex life. What does that do to a marriage? What would it do to an individual to contemplate leaving a partner if you care less? I think there are subtle effects like that that could have affected people and relationships at a huge scale given the many millions of people taking SSRIs. I guess especially prevalent in women as well. I think there's something that wouldn't easily get detected in an experiment but might nevertheless be there on a population level which deserves more attention around this this blunting is caring less that kind of yeah insidious issues there. With psychedelics, sure they have that really long history if we take say psilocybin. We're not talking about a few decades. We're talking about a few millennia. So they were medicines thousands of years ago for certain cultures across the world and now they're re-emerging as medicines today. So that's the positive sort of romantic perspective that is fair but have we always had the quality of science and know-how that we have today and maybe there are some associations that necessarily wouldn't have been picked up by cultures using psychedelic plant medicines you know hundreds or thousands of years ago. So there are things like for example and yeah this is a one we had to be very careful with but psychedelics appear to promote growth in the brain. We know quite clearly from cellular work and rodent work that they'll promote synaptogenesis. So this isn't the growing of new neurons that would really be something. This that doesn't really happen. It's the growth of anatomical components of the existing neurons that they grow more leafy bits and branchy bits will say yeah they don't grow more new trees than neurons themselves but they'll grow their foliage and actually though it's the foliage that is quite reliably impacted by stress and adversity. You lose foliage it's like storm stripping the branches of these trees, these neurons. So there may be a recovery of the foliage of neurons with psychedelics so that's a good growth we think we make that extrapolation because you see that foliage go down with stress and adversity you see it come back potentially with psychedelics so that's something genuinely to be pretty excited about. However could you could you ever get bad growth? I mean the perhaps the most obvious example of bad growth is cancer. I don't think psychedelics are cancer causing. I've never seen that evidence anywhere. I mean people played with that possibility in the 60s really I think motivated by the scare mongering and the political interference at that time that psychedelics could be mutagenic but no evidence was found for that. However there has been a mouse study grafting in a brain tumor into these poor mice. The found that psychedelics could accelerate the growth of those grafted in brain tumors. And so that's just a bit of a cause for some concern or careful reflection if say you know you have someone with a brain tumor to take a psychedelic in such a context could accelerate the growth of the tumor itself. I mean there are other questions there around is the brain tumor such that this is terminal cancer and might you be treating the individuals mental health and relationship to death in which case could you justify the treatment for the sake of having you know good quality of life or a better quality of life in the time remaining even if it accelerates the death itself. So there are sort of deep and important philosophical questions there around that. So yeah there are things like that there's also I mean that's going to something quite biological in terms of a relationship with cancer cells and their growth. What about something more psychological you know psychedelics their power for healing you could say is matched by their power for harms psychological harm that the drugs are so potent in their action on consciousness. The experience isn't pleasant as a rule. If anything, it's more on the side of unpleasant, it's challenging, it's difficult. And that message is lost on people often when they hear that they can treat depression, for example, psychedelics. But that's really psychedelic therapy, can treat depression. And they might take a psychedelic, have an awful experience, hellish experience and think, what, this is meant to be medicine. But I think that's one of the harms that could easily be underappreciated with psychedelics. The experience is tough often. It's difficult, it's often unpleasant, if not distressing. And if not properly understood and supported, that can be, that can set you back in terms of your mental health, rather than, you know, catalyzing an improvement. And so, yeah, that might be one way that people misunderstand psychedelics, get it wrong, and could be harmed because of it. So that's a big caveat I would put on on this whole psychedelic renaissance and interest in the therapeutic potential and power.
01:31:22.000 --> 01:32:29.000
One area that's becoming really popular, and there's more work going on is this, what people are calling the new field of metabolic psychiatry. This link between mental health and metabolic health, which, you know, metabolic health is very much linked to mitochondrial function. And, you know, at a high level for those unacquainted, right, mitochondria are generating most of the ATP for ourselves and doing a number of other things that are crucial. If your mitochondria are working properly in your neurons, which have a lot of mitochondria because they're very metabolically expensive, then your neurons aren't gonna work properly, and if your brain's not working properly, well, that's basically recipe for, you know, potential mental health problems. So there's a lot of excitement right now about, you know, mental health through the lens of mitochondrial function and making people's metabolism healthier in their brain as a way to treat mental
health issues. Is there anything that we know about right now in terms of how psychedelics affect metabolism with regards to mitochondrial function in the brain? Are people looking at that right now? Is anything out there?
01:32:29.000 --> 01:33:55.000
They are looking at it and I've just seen a paper pop up, I think just yesterday about markers of mitochondrial functioning and then improving, so that the mitochondrial health, the marker of it, improving post-solosybin therapy. In this case, in the treatment of mood symptoms linked to Parkinson's. So patients with Parkinson's disease, not treating the core pathology, but treating the depression or the low mood that can come with having the Parkinson's. And so that's interesting. It was a small sample, it was a simple design, not controlled as far as I remember in terms of having a control condition to compare to, so single arm. But still it was signal and signal in an objective biological domain that deserves some interest and further work. We are collecting biosampals both from saliva and blood that we ship off to those with a specialism in looking at markers of mitochondrial functioning, Martin Picard at Columbia,
01:33:55.000 --> 01:33:57.000
is going to be analyzing our samples
01:33:57.000 --> 01:34:25.000
and we'll have samples from a large study, which actually is double blind and two arm and randomized. So yeah, up to at least 100, hopefully, samples, I mean the study will have 120 people, but whether we always get good samples from everyone, it's hard to do.
01:34:25.000 --> 01:34:36.000
So the study basically, you give something like psilocybin to some people, you don't give it to others, and then among other things, you're gonna take their blood and measure various markers of mitochondrial function.
01:34:36.000 --> 01:35:41.000
That's right, yeah, so we take the samples pre and post, post would be like a month post, I think, if I remember rightly. And this is a study actually with an inert placebo, half of the people, 60 people versus a big dose of psilocybin, just a single dose in 60 people. We've got a further complexity to the trial where we also manipulate the context in which they receive either the placebo or the drug and that context for simplicity could either be described as enriched, matching the enriched conditions in which we do psychedelic therapy with really good psychological support and music listening versus for simplicity, I'll call it an unenriched context, which is more like being dosed in a room that we don't decorate, we don't put any music on. We look after people, but we don't do any psychotherapy. Yeah, that's the basic test. So there's actually four conditions in that. Got it.
01:35:41.000 --> 01:35:45.000
So it's enriched psilocybin, unenriched psilocybin, and then the two conditions for the placebo.
01:35:45.000 --> 01:35:48.000
That's right, same for placebo, yeah. Interesting.
01:35:48.000 --> 01:36:10.000
Well, it'll be interesting to see what comes out
of that. I mean, I know that there's at least one small pilot study that was just published, I think in Parkinson's patients where they looked at GDF 15, I think it is. It's a key Markov mitochondrial stress, and that was affected by psilocybin, I think. So I would imagine if Martin Picard is doing your analysis, he's gonna look at that one and probably everything else we possibly can.
01:36:10.000 --> 01:38:24.000
Yeah, I think Martin's a common collaborator and yeah, I know that team, it wasn't my lab, but I know the lab and it's a really exciting study and potential indication for psychedelics. The pilot study also found some improvements in motor functioning actually. So even in core pathology, it's just, we can't say at this stage no one can, whether those were sort of a direct consequence of an action of the psilocybin or somehow sort of secondary to the mood improvements. So we need to just manage expectations there a bit. I often asked about psychedelics for neurological disorder. People make extrapolations like, oh, if you can do typically they would say, given that psychedelics promote neuroplasticity, can they not treat neurodegenerative disorders like Alzheimer's and Parkinson's? And I just say, let's be careful there. We don't want to over promise over extrapolate. There's evidence of synaptogenesis, the growth of branchy bits in mice and dishes with psychedelics. Probably happens in human brains, we don't know that yet. But growing the synapses, the branchy bits isn't recovering the brain from the processes that occur in neurodegenerative disorders. So let's just be careful, we should do the tests absolutely, but it's not clear and compelling to me that it's gonna work so well. I would say I think it's compelling that psychedelic therapy can advance mental healthcare. Yeah, quite considerably. It won't be a simple process, won't be easy. It will come with major challenges, several different types of challenges, but I do think taking a big picture, it can really improve, really be a substantial improvement to mental healthcare going forwards. And that's really exciting.
01:38:24.000 --> 01:38:44.000
What's maybe another example of something that you're working on that's not out yet, that you can at least tell us about it, the level of the question you're tackling and what you hope to learn, are you doing any other clinical trials? And particularly interesting things that are new or avenues that you're exploring that maybe you haven't published on yet.
01:38:44.000 --> 01:43:46.000
Yeah, well, we'll have a trial report coming soon on fibromyalgia syndrome, which is exciting, some really good clinical improvements there, multi-domain improvements in general functioning in that population and some mechanistic markers of how this is working, big increases in brain entropy, brain activity becomes more somewhat chaotic, random, unpredictable under the psychedelic and the magnitude of that predicts psychological insight, but predicts improvements in symptom severity and improvements in general functioning. And that's a replication of some earlier work where we found that this so-called intropic brain effect that psychedelics do very reliably, most dependently relates to psychological insight, which relates to improvements in mental health. So we're starting to get a sort of multi-domain perspective on the causal action of psychedelic therapy that's not drawing just on abstract psychological phenomena like psychological insight and emotional breakthrough. but also leveraging some insights in terms of changes in brain function that relate to these psychological phenomena. And I'm excited about that. This is a tropic brain effect. We're starting to get good markers of it across brain imaging modalities. We've got an exciting marker of it in the GFMRI. This particular metric called normalised global spatial complexity and GSC first published on, at least brought my attention to it, came from Josh Siegel, then out of Wachu. He's now in New York, I believe. And that was cellocycling desynchronising brain activity, published in Nature, I think in 24 now, 2024. That marker is coming through again in some of our UCSF research where we've done deep sampling on a small number of individuals, up to 14, recording their brain activity in some cases for 12 hours. So they amassed a total of 12 hours in the MRI scanner being recorded with FMRI. And then we do subjective ratings every so often. We have them rate things like psychological insight and we give them cellocycling in that study and let's see three quarters of the data of the so nine of the 12 hours is under the influence of cellocycling. So that's a deep sampling, you know, you go deep in an individual and get a lot of data per individual. And we're finding a relationship between this increase in NGSC which could be thought of as brain activity, yes becoming more desynchronised across the brain. So you pick a region at the front, it would be likely that its activity would be desynchronised with a region at the back. I'm just making it super simple. And just across the brain different regions are going to have activity that is out of sync with another region. So generalised global desynchrony. And it's the entropic brain effect but in the spatial domain versus in the temporal domain where if you're looking at oscillating or fluctuating activity, those fluctuations, those up and downs in the polarity of the activity is more erratic. That would be the entropic brain in the temporal domain. And typically that's how we record that phenomenon and compute that phenomenon with a data from a modality like EEG or MEG. So looking at so called brain waves. So that entropic brain effect crosses modalities. We see it in EEG, MEG, FMRI and it relates to the intensity of the trip. And what we're finding increasingly is that it quite reliably relates to psychological insight. And people will remember from earlier in our conversation that we're
finding that the psychological insight is a strong predictor of therapeutic outcomes. So we're starting to join the dots more and more between domains, between mind and biology if you want, starting to fill in the pieces. So I'm excited about that too.
01:43:46.000 --> 01:43:56.000
What was it like writing this book? I think this was my first book for the public. What was it like? Was it difficult how long did it take you?
01:43:56.000 --> 01:46:26.000
Yeah, it took me, well, I had a contract that gave me two years, I asked for two years and it worked out that way. I delivered it on time but I couldn't have done it any faster and produced something that I was happy about. I'm happy about what I did. It very much covers a couple of decades of work I've done on the neuroscience of psychedelics and the psychology and the therapeutic potential. It was a great experience, it was a passion project very much. I occupied every waking thought more or less, I'm exaggerating but you know, it was it was there as an undercurrent all the time and probably in my dreams as well. So I really gave it my full being this book. Nothing was left out. I enjoyed that. I was deeply immersed in it. It was hard but it was a labour of love. It had to be hard. I think they say something like easy reading takes hard writing or something like that. So I had that in mind that I was right to be faffing as much as I was. Maybe the editor and others wanted me to just put it to bed towards the end but I had to keep editing. Also in the sub editing that came in, I had to make these changes and noticing, I don't know, repeat phrases or terms that I had to address. So yeah, there was a lot of attention to detail and it very much a labour of love. I hope people appreciate that when they read it. I'm excited for that. I'm starting to get really positive feedback already. So yeah, I'm excited for all of that.
01:46:26.000 --> 01:46:31.000
Do you think the book would have ever happened if you hadn't have had that experience when you were
01:46:31.000 --> 01:48:19.000
14? Of course not. Yeah, it all started there. Yeah, it's a funny old thing. People might say, could you ever be a psychedelic scientist without personal experience? Well, I think you could. We've had people come into our team at different points and bring a really useful skill set. Maybe there are psychotherapists with expertise in eating disorders and they come in and they really complement us and move with us along. Or there are brain imaging analysts and they've never taken a psychedelic and they come in and they do some really cool sophisticated analysis that moves the needle on the action. So you don't have to have had personal experience. I think if you want a rounded perspective and a deep perspective, it would depreciate your ability. There would be a cost to what you could do if you didn't have personal experience. I think the personal experience that I've had does add validity to what I've done here. I don't think
it's a bias in a negative sense. I think it's a bias in a positive sense that I know this stuff pretty intimately. So, you know, self-experimentation is still experimentation, it's still testing. And phenomenology, as I've been saying, is very much part of the picture. So, to know that and to be able to describe it, I think really adds a richness to what I produced and more generally just
01:48:19.000 --> 01:48:40.000
to the work that I do. And who would you say this book is for? Is it for anyone interested in psychedelics or does someone should someone already have sort of a background in the science and the type of work you do? It's really for everyone. It's written that way. So it's not for the
01:48:40.000 --> 01:51:27.000
just the initiated, it's not just for the community. It's really for everyone. So, you know, I might have like my parents in mind, they've never taken a psychedelic and they don't know neuroscience. They don't really know psychology, but they've read it and enjoyed it and learned to heck of a lot, including some personal stuff about me that they didn't know. But, yeah, and I also think for young people, there's a sort of, yeah, there is a, you know, almost a persona that I have in my mind's eye when I've written this, which is a young person. Maybe it's even me. Maybe it's me as a teenager like curious about stuff, quite vulnerable, kind of insecure doing this. And maybe with questionable intentions was I trying to escape, you know, was it was that the psychology behind what I did there? And I want to help that person and educate them. I took LSD at 14 without any real education about a mind. There wasn't any deep education about drugs. I knew way more than my parents, she'd just paraded the message, say no to drugs and so on. I knew more than them, but I still knew next to nothing about psychedelics. So I do want to educate, and I think it's young people, it's young people that could otherwise come to harm. I have wondered whether I was quite fortunate, not to really harm myself or other people, by my actions, it could have happened, it does happen. Tragides do happen with psychedelics. And so I think I'm trying to keep people safe who will be like I was, but they're living right now. And they could come to the topic of psychedelics through all the hype that's happening, misunderstand them and come to harm. And so I think that's the persona, that's the demographic that I most want to help. But I think that can trickle through to like parents of those individuals. So it doesn't have to be that specific demographic, but of all demographics, I think that's the one
01:51:27.000 --> 01:51:32.000
else you want them to know about the book.
01:51:32.000 --> 01:53:52.000
It's hard to, so general, that it's hard to stay. The ending of the book starts to bring in, as you might naturally expect, it starts to bring in some bit of spirituality and philosophy, I guess, around sort of, how to live life. And again, my editor kind of questioned that and said, you know, why do you need to mention Buddhism? That would be a book in its own right. And sort of encouraged me to either take that out or edit it. I did edit it down to the essentials, but I would say that the inclusion of that material, and it doesn't have to be so, you know, a denomination specific as Buddhism with a capital B, maybe more like Buddhist, you know. It's spirituality, it's borrowing from, you know, Buddhist philosophy, Hindu philosophy, Eastern philosophy, generalistic Taoism. And that had to be there. I feel very strongly that that is the most important most important realization from psychedelic use. It is a re-realization or remembering about, about, you know, perennial truths or wisdoms that can help us as a species. And I could not include that, it had to be in. It's pluralistic, it's not me promoting Buddhism per se, but it is me saying, look, these wisdom teachings, I think they are maybe spotlighted or exposed in the depth of their truth and appeal through psychedelic experiences. And to know that there is that beautiful synergy and harmony and symbiosis is a really important message that I could give people. And so I do give them that at the end of the book. Yeah.
01:53:52.000 --> 01:54:09.000
All right, well, Dr. Robin Carhart-Harris, thank you very much for your time. I really appreciate it. We did another discussion. So if people want to dive deep on some of your ideas around the entropic brain principle and get a little bit more into some of the neuroscience there, check out the first episode. But yeah, I really appreciate your time once again and thank you very much.
01:54:09.000 --> 01:54:11.000
Thank you, Nick. It's been a pleasure.
01:54:11.000 --> 01:56:00.867
Here, in the way to support my efforts is to visit my support page at mindandmatter.substack.com. A link to that page is in the episode description or you can search for it on the Substack page itself. The support page has an up to date list of my affiliate partners. These are companies I work with. And if you buy those products through those links or using the discount codes provided, those will get you a great deal on a variety of products related to optimizing physical, metabolic, or mental health and vitality. These are all products I use myself and some of them are directly related to podcast episodes or formulated by mind and matter guests. For example, there's a great product called KetoCitra formulated by a kidney biologist who is on episode number 186. It contains the ketone body BHB together with several minerals in a precise ratio formulated with kidney health in mind. There are also links to products like physical, technology devices to track your metabolic health, digital applications to help you find and learn about food and consumer products and more. One product I use every day is the AquaTru water filter. I recommend this to everyone because it gets everything out of your drinking water. Heavy metals, microbes, endocrine disruptors, microplastics, you name it. Other charcoal or gravity based filters that a lot of people use don't get everything out. They just get some of the stuff out. So I really like the AquaTru product. You can look for a link to my affiliate partners on my support page or directly in the episode description to this episode or you can go to mindandmatter.substack.com to find it there.